Arabic Arabic English English French French German German
dark

Data Integrity Issues in Bioequivalence Studies

Nilufer Tampal, PhD, Acting Deputy Director of the Office of Bioequivalence, discusses the FDA’s bioequivalence data expectations.
Learn more at: https://www.fda.gov/drugs/news-events-human-drugs/generic-drugs-forum-2021-lifecycle-generic-drug-04282021-04292021
——————– 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  

Upcoming Training – https://www.fda.gov/cdersbia   
SBIA Listserv – https://public.govdelivery.com/accounts/USFDA/subscriber/new?topic_id=USFDA_352
SBIA 2021 Playlist – https://youtube.com/playlist?list=PLey4Qe-UxcxYS1MaTusSgyifQDqdeepyD
SBIA LinkedIn – https://www.linkedin.com/showcase/cder-small-business-and-industry-assistance  
SBIA Training Resources – https://www.fda.gov/cderbsbialearn  
Twitter – https://twitter.com/FDA_Drug_Info  
Email – CDERSBIA@fda.hhs.gov  
Phone – (301) 796-6707 I (866) 405-5367

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Global Generic Drug Landscape

Next Post

Bioavailability/Bioequivalence Site Evaluation During the Pandemic

Related Posts

Panel Discussion

Sarah Ibrahim, Nilufer Tampal, Makini Cobourne-Duval, and Victoria Keck discuss audience questions. Learn more at: https://www.fda.gov/drugs/news-events-human-drugs/generic-drugs-forum-2021-lifecycle-generic-drug-04282021-04292021 ——————–  FDA…
Read More
Total
0
Share